Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PLX 
Protalix Biotherapeutics Inc (PLX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: PLX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.4% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 155.48M USD | Price to earnings Ratio 21.67 | 1Y Target Price 14 |
Price to earnings Ratio 21.67 | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta -0.23 | 52 Weeks Range 0.99 - 3.10 | Updated Date 09/16/2025 |
52 Weeks Range 0.99 - 3.10 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.13% | Operating Margin (TTM) 7.49% |
Management Effectiveness
Return on Assets (TTM) 6.05% | Return on Equity (TTM) 15.99% |
Valuation
Trailing PE 21.67 | Forward PE 3.58 | Enterprise Value 127428624 | Price to Sales(TTM) 2.51 |
Enterprise Value 127428624 | Price to Sales(TTM) 2.51 | ||
Enterprise Value to Revenue 2.06 | Enterprise Value to EBITDA 12.26 | Shares Outstanding 79732096 | Shares Floating 60482390 |
Shares Outstanding 79732096 | Shares Floating 60482390 | ||
Percent Insiders 10.54 | Percent Institutions 15.14 |
Upturn AI SWOT
Protalix Biotherapeutics Inc
Company Overview
History and Background
Protalix Biotherapeutics Inc. was founded in 1993 in Israel. It is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx plant cell-based protein expression system. A major milestone was the FDA approval of Elelyso for Gaucher disease.
Core Business Areas
- Gaucher Disease: Develops and markets Elelyso (taliglucerase alfa) for the treatment of Gaucher disease.
- Fabry Disease: Developing PRX-102 (pegunigalsidase alfa) for the treatment of Fabry disease. Currently under regulatory review in the US.
- Other Pipeline Products: Developing other pipeline products using the ProCellEx platform, targeting other genetic disorders.
Leadership and Structure
The leadership team includes Dror Bashan (President and CEO). The company has a typical biotech structure, with departments focused on R&D, manufacturing, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Elelyso: Elelyso (taliglucerase alfa) is a plant cell-expressed recombinant glucocerebrosidase enzyme. It's used for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease. Competitors are Sanofi's Cerdelga and Takeda's Vpriv, although the market is shifting with gene therapies.
- Market Share Data: Elelyso market share is relatively small compared to competitors and is difficult to pinpoint due to changing market conditions and emerging therapies.
- Market Share Data: This product is not yet approved, so there is no current revenue or market share data available. Projections vary based on approval and uptake.
- PRX-102 (pegunigalsidase alfa): PRX-102 (pegunigalsidase alfa) is a chemically modified version of the recombinant alpha-galactosidase A enzyme. It is in development for the treatment of Fabry disease. Competitors are Sanofi's Fabrazyme and Takeda's Replagal. Expected to compete in $1 billion+ market.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. Companies developing therapies for rare genetic diseases face high development costs, regulatory hurdles, and commercialization challenges.
Positioning
Protalix focuses on developing treatments for genetic disorders using its ProCellEx platform. Its competitive advantage lies in its plant cell-based expression system, which offers potential cost and scalability advantages.
Total Addressable Market (TAM)
The TAM for Gaucher and Fabry disease treatments is significant (over $1 billion for Fabry alone), and Protalix aims to capture a portion of this market with its innovative therapies. Success of PRX-102 is critical to their market presence.
Upturn SWOT Analysis
Strengths
- Proprietary ProCellEx platform
- FDA-approved product (Elelyso)
- Strong pipeline focused on rare diseases
- Experienced management team
- Partnerships with major pharmaceutical companies
Weaknesses
- Limited commercial infrastructure
- Reliance on a few key products
- Competition from larger pharmaceutical companies
- Dependence on regulatory approvals
Opportunities
- Expanding into new therapeutic areas
- Developing new products using ProCellEx platform
- Partnering with other companies
- Entering new markets
Threats
- Regulatory setbacks
- Competition from new therapies
- Patent expirations
- Economic downturn
Competitors and Market Share
Key Competitors
- SNY
- TAK
Competitive Landscape
Protalix faces intense competition from larger pharmaceutical companies with more resources. Protalix's advantage is its novel ProCellEx platform and focus on unmet needs in rare diseases. They are a smaller player in the market.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent and dependent on successful product launches and partnerships.
Future Projections: Future growth depends heavily on the approval and commercial success of PRX-102 and other pipeline products. Analyst estimates vary.
Recent Initiatives: Recent initiatives include the regulatory submissions for PRX-102, expanding manufacturing capacity, and pursuing new partnerships.
Summary
Protalix is a biotech company focused on rare diseases with a proprietary plant cell expression platform. Its success hinges on the approval and commercial success of PRX-102. While they have an approved product in Elelyso, they face significant competition. Regulatory setbacks and market competition are key risks. Future success is dependent on execution and expanding its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate. Financial data requires real-time API access and may be outdated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protalix Biotherapeutics Inc
Exchange NYSE MKT | Headquaters Hackensack, NJ, United States | ||
IPO Launch date 1998-05-15 | President, CEO & Director Mr. Dror Bashan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 213 | Website https://www.protalix.com |
Full time employees 213 | Website https://www.protalix.com | ||
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.